공고 • Jul 16
Regen BioPharma Inc Settles Lawsuit With Trillium Partners LP Regen BioPharma Inc. reported that on April 13, 2026 a complaint was filed against the Company in the Superior Court of California, County of San Diego . Trillium Partners, LP,(the “ Plaintiff”), who has acquired rights to $398,740 of claims against the Company, sought damages in that amount along with attorneys’ fees and costs. On May 14, 2026 the Company and the Plaintiff entered into a Settlement and Mutual Release Agreement (“Agreement”). Pursuant to the terms and conditions of the Agreement following the entry of an Order by the Court after a fairness hearing pursuant to Section 3(a) (10) of the Securities Act of 1933 (the “Securities Act”), and Section 25142 of the California Corporations Code (the “Corporations Code”) and the delivery by the Plaintiff and the Company of the Stipulation of Dismissal in settlement of the Claims, the Company shall issue and deliver to the Plaintiff shares of its Common Stock or Series A Preferred Stock (the “Settlement Shares”) in one or more tranches as necessary, and subject to adjustment and ownership limitations as set forth in the Agreement, sufficient to generate proceeds such that the aggregate Remittance Amount equals the Claim Amount. The Remittance Amount shall mean sixty five percent (65%) of Net Proceeds of the sale of Settlement Shares. On July 10, 2026, after a Fairness Hearing, the Superior Court of California issued an order approving issuance of the Settlement Shares pursuant to Section 3(a) (10) of the Act and Section 25142 of the Corporations Code . 공고 • Nov 17
Regen BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $1 million. Regen BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $1 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 100,000,000
Price\Range: $0.01 공고 • Sep 24
Regen Biopharma, Inc. Announces Update on Its Application for Orphan Drug Status to the U.S. Food and Drug Administration for Hemaxellerate Regen BioPharma, Inc. announced the Company will be presenting an update on its application for Orphan Drug status to the U.S. Food and Drug Administration (FDA) for HemaXellerate. This therapy is anticipated being used in treating plastic anemia. Additionally the Company anticipates HemaXellerate may be used in addressing the side effects of Chemotherapy, a market of several billions of dollars. 공고 • Sep 05
Regen BioPharma, Inc. Explores Expanded Use of HemaXellerate for Chemotherapy-Induced Bone Marrow Suppression Regen BioPharma, Inc. announced its ongoing efforts to expand the clinical development of HemaXellerate, its novel cellular therapy, to address chemotherapy-induced bone marrow suppression, a serious and common complication in cancer patients undergoing cytotoxic treatments. This represents potentially a market in excess of $1 billion per year in just the US. Following the recent submission of an Orphan Drug Application for the treatment of aplastic anemia, Regen BioPharma is broadening its focus to include non-orphan indications where HemaXellerate may offer a transformative approach to unmet medical needs in oncology supportive care. Current standard-of-care treatments include: Colony-Stimulating Factors (e.g., G-CSF, GM-CSF): Promote white blood cell production but have limited effects on red cells or platelets. Erythropoiesis-Stimulating Agents (ESAs): Used for anemia but carry cardiovascular and thrombotic risks. Platelet transfusions: Temporary and often limited by availability and patient tolerance. These therapies are largely single-lineage, symptomatic, and reactive. They do not address the root cause: damaged or suppressed hematopoietic stem cell function. HemaXellerate: A Multi-Lineage Regenerative Approach: In contrast, HemaXellerate is designed to stimulate the body's own hematopoieticstem cells, enhancing the recovery of all three major blood cell lines--erythrocytes, leukocytes, and platelets--simultaneously. Unlike traditional treatments that target specific symptoms or lineages, HemaXellerate acts upstream by restoring bone marrow microenvironment function and promoting endogenous hematopoiesis. The stem cell literature indicates that HemaXellerate will: Accelerate bone marrow recovery following cytotoxic injury; Enhance resilience to repeated chemotherapy cycles; Reduce dependence on transfusions and secondary supportive drugs. 공고 • Aug 30
Regen BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $5 million. Regen BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 25,000,000
Price\Range: $0.1 to $0.2 공고 • Aug 15
Regen BioPharma, Inc. Provides Further Insight into Its Planned Phase 1 Clinical Trial of HemaXellerate Regen BioPharma, Inc. provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company's innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this therapy in markets poised for significant growth. Regen sees substantial potential in treating chemotherapy-induced bone marrow suppression, a market projected to be valued at well in excess of $1 billion annually. HemaXellerate is designed to stimulate bone marrow transplantation following injury caused by autoimmune conditions, chemotherapy, or radiation. HemaXellerate are comprised of cells extracted from the patient's own fat tissue and processed using a proprietary method to induce a biological response in the patient that heal damaged bone marrow and improves the body's ability to generate healthy blood cells. To ensure the trial's success, Regen BioPharma has partnered with a clinical research organization (CRO) known for its expertise in conducting complex trials. Once initiated, the study is expected to reach completion within 12 to 14 months. Opportunity: Aplastic anemia is a rare disease with high unmet medical need, offering the potential for accelerated regulatory pathways and market exclusivity. Massive Market Potential: Expansion into chemotherapy-induced bone marrow suppression could unlock a multi-billion-dollar market. Strategic Execution: Collaboration with a leading CRO ensures focused execution and timeline adherence. 공고 • Aug 13
Regen BioPharma, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5 million. Regen BioPharma, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 16,666,667
Price\Range: $0.3
Discount Per Security: $0 공고 • May 30
Regen BioPharma, Inc. Files Form 15 Regen BioPharma, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. 공고 • Dec 27
Regen BioPharma, Inc. Files Form 15 Regen BioPharma, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. 공고 • Nov 20
Regen Biopharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate Regen BioPharma, Inc. provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company’s innovative stem cell-derived therapy, which has already received FDA clearance. While the initial focus is on treating aplastic anemia, Regen BioPharma is evaluating expanded applications for this therapy in a market poised for significant growth. HemaXellerate is designed to stimulate bone marrow regeneration following injury caused by autoimmune conditions, chemotherapy, or radiation. While the company’s initial target is aplastic anemia a rare orphan indication it sees substantial potential in treating chemotherapy-induced bone marrow suppression, a market valued at over $1 billion annually. This is evidenced by the success of products like Neulasta, which addresses similar unmet needs. To ensure the trial’s success, Regen BioPharma has partnered with a clinical research organization known for its expertise in conducting complex trials. Once initiated, the study is expected to reach completion within 12 to 14 months. 공고 • Oct 30
Regen BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $2 million. Regen BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 10,000,000
Price\Range: $0.2
Discount Per Security: $0 공고 • Feb 12
Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells On February 7, 2024 Regen Biopharma, Inc. filed a provisional patent application with the United States Patent and Trademark Office covering compositions of matter, protocols and treatment means for accelerating hematopoietic reconstitution after an insult or chronic pathology by administration of stem cell derived endothelial progenitor cells or endothelial cells. 공고 • Nov 15
Regen BioPharma, Inc. Outlines Future Steps in CAR T Program Regen BioPharma, Inc. has previously discussed initiation of its DuraCAR CAR T-cell therapeutic. This program is designed to create chimeric antigen T-cells that silence the gene for NR2F6. As part of the development of this program, it was discovered that NR2F6 mRNA was greatly increased, thus identifying new, unexpected and potentially extremely useful findings in developing cell therapy treatments for autoimmune disorders. The Company is now preparing a series of in vitro experiments to determine if these DuraCAR cells are indeed immunosuppressive, rather than possessing anti-tumor activity as originally envisioned. Future experiments will then be designed to optimize these cells for protecting against major autoimmune disorders such as type 1 diabetes, colitis and arthritis. 공고 • Oct 26
Regen BioPharma, Inc Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program Regen BioPharma, Inc. has previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic while also identifying new, unexpected and potentially extremely useful findings in developing celltherapy treatments for autoimmune disorders. The Company has now received the complete set of confirmatory data performed by a second contract research organization (CRO) which is independent of the CRO which performed the initial experiments. These data confirm that T cells which express the chimeric antigen receptor (CAR) construct targeting CD19 and expressing siRNA for NR2F6 had high expression levels of NR2F6 mRNA. NR2F6 is considered an immune checkpoint and thus increasing its activity is likely to lead to immune suppression. 공고 • Oct 19
Regen Biopharma, Inc. Expects Second Phase of Confirmatory Study Shortly Regen BioPharma, Inc. announced currently developing a genetic approach to regulating NR2F6 levels in human T cells. The Company has recently received unexpected and potentially extremely useful data from one of its contract research organizations (CRO) retained to perform experimental studies on the Company's DuraCAR CAR T-cell therapeutic. These studies demonstrated that T cells which express the chimeric antigen receptor (CAR) construct expressing siRNA for NR2F6 can be successfully created. Once the Company receives the data, it will analyze the results and report the findings in a press release in order to keep the company's shareholders informed of its progress. 공고 • Sep 21
Studies on Regen Biopharma, Inc.'s Duracar Indicate Potential Suppression of Autoimmunity, Company Retains Contract Research Organization to Conduct Additional Confirmatory Studies Regen BioPharma Inc. had previously discussed initiation of a series of experiments to validate its DuraCAR CAR-T cell therapeutic. The first phase of in vitro experiments successfully synthesized and expressed in transfected cells the chimeric antigen receptor (CAR) construct targeting CD19 and NR2F6. However, a second set of experiments yielded unexpected results whereby siRNAs designed to suppress NR2F6 mRNA expression yielded the opposite result. The company has engaged a contract research organization (CRO) that is independent of the CRO which performed the second set of experiments to determine if these surprising findings are reproducible. If confirmed, these results could lead to the development of a therapy whereby T-Cells that suppress autoimmunity can be created.